Impact of inhaled fluticasone propionate/salmeterol on health-related quality of life in asthma: A network meta-analysis

Maneechotesuwan, Kittipong; Singh, Dave; Fritscher, Leandro Genehr; Dursunoğlu, Neşe; Pg, Abhijit; Phansalkar, Abhay; Aggarwal, Bhumika; Pizzichini, Emílio; Chorazy, Justyna; Burnett, Heather

doi:10.1016/j.rmed.2022.106993

Cited by 4 publications

(1 citation statement)

References 67 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Метаанализ, посвященный сравнению фиксированных доз флутиказона пропионата/салметерола два раза в день с только ИГКС и другими сочетаниями ИГКС/ ДДБА, в т. ч. с терапией в режиме MART с точки зрения улучшения качества жизни, связанного со здоровьем (HRQoL), показал значимое преимущество в сравнении с плацебо, тогда как с MART-режимом эффект был аналогичным [32].…”

Section: Chronic Pulmonary Diseasesunclassified

Combined therapy of broncho-obstructive pathology: two solutions to one problem

Vizel,

Vizel

2023

Medicinskij sovet

View full text Add to dashboard Cite

Chronic broncho-obstructive pulmonary diseases – bronchial asthma (BA) and chronic obstructive pulmonary disease (COPD) – are a serious clinical problem and an economic burden for practical healthcare. The purpose of the scientific review is to track the evolution of views on the use of bronchodilators and inhaled corticosteroids (ICS) in these diseases and to analyze modern approaches to treatment based on domestic and international guidelines. COPD treatment is aimed at two pathogenetic components – inflammation of the bronchi and the formation of emphysema. The basis of basic therapy remains the use of long-acting bronchodilators of two classes. Treatment of asthma is directed primarily at chronic inflammation of the airways using long-acting bronchodilators. The basis of basic therapy for asthma is the use of inhaled glucocorticosteroids. Currently, the same combinations of bronchodilators and ICS are recommended for both asthma and COPD. One direction is based on the use of ICS with formoterol, a 12-hour drug with a fast onset, in which the drug can be used on demand. The second direction is based on the constant use of ICS/LABA only on a regular basis, but with the ability to use bronchodilators on demand. In this case, ICS with high affinity are more often used. An important component of treatment is adherence to medical prescriptions and the availability of different types of drugs for patients in real clinical practice. At present, conditions have been created in Russia for the implementation of both the treatment of patients with asthma and the treatment of patients with COPD with frequent exacerbations and eosinophilia based on import substitution with modern drugs.

show abstract

Section: Chronic Pulmonary Diseasesunclassified

Combined therapy of broncho-obstructive pathology: two solutions to one problem

Vizel,

Vizel

2023

Medicinskij sovet

View full text Add to dashboard Cite

show abstract

Decreased salivary beta-defensin 2 in children with asthma after treatment with corticosteroid inhaler

Moosavi

Hosseinizade²,

Panahi³

et al. 2023

Eur Arch Paediatr Dent

View full text Add to dashboard Cite

Insights into Inhalation Drug Disposition: The Roles of Pulmonary Drug-Metabolizing Enzymes and Transporters

Dong,

Zhuang

2024

IJMS

View full text Add to dashboard Cite

The past five decades have witnessed remarkable advancements in the field of inhaled medicines targeting the lungs for respiratory disease treatment. As a non-invasive drug delivery route, inhalation therapy offers numerous benefits to respiratory patients, including rapid and targeted exposure at specific sites, quick onset of action, bypassing first-pass metabolism, and beyond. Understanding the characteristics of pulmonary drug transporters and metabolizing enzymes is crucial for comprehending efficient drug exposure and clearance processes within the lungs. These processes are intricately linked to both local and systemic pharmacokinetics and pharmacodynamics of drugs. This review aims to provide a comprehensive overview of the literature on lung transporters and metabolizing enzymes while exploring their roles in exogenous and endogenous substance disposition. Additionally, we identify and discuss the principal challenges in this area of research, providing a foundation for future investigations aimed at optimizing inhaled drug administration. Moving forward, it is imperative that future research endeavors to focus on refining and validating in vitro and ex vivo models to more accurately mimic the human respiratory system. Such advancements will enhance our understanding of drug processing in different pathological states and facilitate the discovery of novel approaches for investigating lung-specific drug transporters and metabolizing enzymes. This deeper insight will be crucial in developing more effective and targeted therapies for respiratory diseases, ultimately leading to improved patient outcomes.

show abstract

Impact of inhaled fluticasone propionate/salmeterol on health-related quality of life in asthma: A network meta-analysis

Cited by 4 publications

References 67 publications

Combined therapy of broncho-obstructive pathology: two solutions to one problem

Combined therapy of broncho-obstructive pathology: two solutions to one problem

Decreased salivary beta-defensin 2 in children with asthma after treatment with corticosteroid inhaler

Insights into Inhalation Drug Disposition: The Roles of Pulmonary Drug-Metabolizing Enzymes and Transporters

Contact Info

Product

Resources

About